Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Promising new treatments for multiple sclerosis

MEDIA RELEASE

Promising new treatments for multiple sclerosis

15 August 2014

New treatments for multiple sclerosis (MS) using common anti-psychotic agents have been discovered by Victoria University of Wellington researchers.

The study led by Dr Anne La Flamme, an associate professor in the School of Biological Sciences and head of the MS research programme at the Malaghan Institute of Medical Research, based at Victoria, shows the potential of clozapine and risperidone to effectively treat MS.

MS, a neurological disease which affects one in every 1,400 New Zealanders, is caused by immune cells invading the brain and causing inflammation. It leads to impaired vision and coordination and, eventually, paralysis, explains Dr La Flamme.

“While disease-modifying drugs are currently available, they are often effective in only a subpopulation of MS patients and all of these treatments target the disease through traditional immune pathways,” she says.

“What makes our findings so important is that clozapine and risperidone target a very different set of pathways from all other MS drugs, and thus have the potential to treat those MS populations for which no effective therapies currently exist.”

Published this week by international scientific journal PLOS ONE, the study demonstrates that risperidone and clozapine can reduce MS significantly by reducing the inflammation in the brain that causes this disease.

Additionally, this research indicates that the way clozapine and risperidone improve disease outcomes in MS is different from how these agents work to treat mental health disorders.

“By utilising existing therapies, this work may more quickly support improved outcomes for people with MS,” says Dr La Flamme.

This study, funded by the Neurological Foundation of New Zealand, was undertaken in collaboration with Dr Bronwen Connor, an associate professor at the University of Auckland.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Constructions Builds: Consents Top $2 Billion For The First Time

Building consents reached a record $2 billion in March 2017, boosted by new homes and several big non-residential projects, Stats NZ said today. This was up 37 percent compared with March 2016. More>>

Other Stats:

Health: Work Underway To Address Antimicrobial Resistance

As part of a global response the Ministries of Health and Primary Industries have today jointly published ‘Antimicrobial Resistance: New Zealand’s current situation and identified areas for action’ to respond to the changing pattern of antimicrobial resistance in New Zealand. More>>

ALSO:

Employment: Vodafone Announces Family Violence Policy To Support Team

From today, any of Vodafone’s 3,000 workers affected by family violence will be eligible for a range of practical support, including up to 10 additional days of paid leave per year. More>>

Burning Up Over Saturn: Cassini's Grand Finale

With propellant running low, NASA scientists are concerned that the probe might accidentally crash into one of Saturn’s nearby moons, which could contaminate it with Earthling bacteria stuck to the spacecraft. Instead, the spacecraft will be safely "disposed" in Saturn's atmosphere. More>>

ALSO:

Our Fresh Water: Monitoring Report Confirms Serious Challenges For Rivers

• nitrogen levels are getting worse at 55 percent and getting better at 28 percent of monitored river sites across New Zealand • phosphorus levels are getting better at 42 percent and getting worse at 25 percent of monitored river sites across New Zealand More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news